Abstract
Recent years have seen the development of the concept of combination therapy for treating severe fungal sepsis. The advantages of this approach are a potential improvement in patient survival and a reduction in the chance of resistance developing to each of the single agents. The disadvantage is that combining drugs may increase the chance of toxicity. Mycograb® is a genetically recombinant antibody against fungal heat shock protein 90 (hsp90) which is poised to become the mainstay of combination therapy. This paper presents data on how hsp90 is important to fungi and what role it might play in human disease with possible interactions with interleukin 6 and nitric oxide. There is discussion of preclinical data demonstrating synergy in vitro between Mycograb® and amphotericin B and caspofungin. The progress of Mycograb® through a Phase II pharmacokinetic study when used in escalating doses with a liposomal amphotericin B preparation has also been reviewed. The concepts behind a Phase II pivotal study, where Mycograb® or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed.
Keywords: mycograb, hsp, candidiasis, amphotericin b, interleukin, map kinases, nitric oxide, immunotherapy
Current Molecular Medicine
Title: Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy
Volume: 5 Issue: 4
Author(s): R. C. Matthews and J. P. Burnie
Affiliation:
Keywords: mycograb, hsp, candidiasis, amphotericin b, interleukin, map kinases, nitric oxide, immunotherapy
Abstract: Recent years have seen the development of the concept of combination therapy for treating severe fungal sepsis. The advantages of this approach are a potential improvement in patient survival and a reduction in the chance of resistance developing to each of the single agents. The disadvantage is that combining drugs may increase the chance of toxicity. Mycograb® is a genetically recombinant antibody against fungal heat shock protein 90 (hsp90) which is poised to become the mainstay of combination therapy. This paper presents data on how hsp90 is important to fungi and what role it might play in human disease with possible interactions with interleukin 6 and nitric oxide. There is discussion of preclinical data demonstrating synergy in vitro between Mycograb® and amphotericin B and caspofungin. The progress of Mycograb® through a Phase II pharmacokinetic study when used in escalating doses with a liposomal amphotericin B preparation has also been reviewed. The concepts behind a Phase II pivotal study, where Mycograb® or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed.
Export Options
About this article
Cite this article as:
Matthews C. R. and Burnie P. J., Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy, Current Molecular Medicine 2005; 5 (4) . https://dx.doi.org/10.2174/1566524054022594
DOI https://dx.doi.org/10.2174/1566524054022594 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets Maps of cis-Regulatory Nodes in Megabase Long Genome Segments are an Inevitable Intermediate Step Toward Whole Genome Functional Mapping
Current Genomics Soft Condensed Matter in Pharmaceutical Design
Current Pharmaceutical Design Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Soluble Factors of Amnion-Derived Cells in Treatment of Inflammatory and Fibrotic Pathologies
Current Stem Cell Research & Therapy Editorial [Hot Topic: Antimicrobial Peptides, Mainly Defensins in Oral Cavity (Executive Editors: S. Vardar-Sengul and D. Mercola)]
Current Pharmaceutical Design Molecular Allergy Diagnostics as an Adjunct to Conventional Diagnostics in a Secondary Pediatric Referral Center
Recent Patents on Inflammation & Allergy Drug Discovery Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Nevirapine-Based Regimens in Routine Clinical Settings: Results from a Large Italian Cohort of HIV-1 Infected Adults
Current Drug Safety There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Crucial Role of Interferon-γ and Stimulated Macrophages in Cardiovascular Disease
Current Vascular Pharmacology Role of Invariant Natural Killer T (iNKT) Cells in Systemic Lupus Erythematosus
Current Medicinal Chemistry Therapeutic Potential of Targeting TREM-1 in Inflammatory Diseases and Cancer
Current Pharmaceutical Design Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design Recent Advances in Genome-wide Analyses of Plant Potassium Transporter Families
Current Genomics Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Novel Nanocarriers for the Treatment of Wound Healing
Current Pharmaceutical Design